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users. The higher incidence of severe complications with non-
selective NSAID resulted, despite of a lower acquisition price, in
higher costs of those medications compared to meloxicam.
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OBJECTIVES: To compare, in the Spanish setting, the annual
costs associated with the management of adult patients with
rheumatoid arthritis using oral leﬂunomide (Arava®) or a new
presentation of metotrexate (Metoject®, preﬁlled syringes).
METHODS: Due to the absence of any randomized controlled
trial that had showed signiﬁcant differences in effectiveness
between leﬂunomide and metotrexate a cost-minimization analy-
sis has been performed under the Spanish societal perspective.
Data about effectiveness and dose of drugs administered were
obtained from the clinical trial US310, a 12 months-randomised
controlled trial which compares head-to-head 20 mg daily of
leﬂunomide versus 7.15–15 mg weekly of metotrexate. Use of
other medical resources like lab tests and consultations related
with drug monitoring were derived from the manufacturers’
summary of product characteristics. Patient time and productiv-
ity time lost were derived from other published studies and
economic evaluations. RESULTS: Annual drug costs with
leﬂunomide and preﬁlled syringes of metotrexate are 1,112.52€
and 1,438.91€ respectively. Annual monitoring costs amount
680.76€ and 710.26€ respectively. Other direct medical costs
equal up to 677€ and 542€ while indirect costs amount 862€ and
577€ respectively. CONCLUSION: Metoject®, a new presenta-
tion of metotrexate has been recently launched in Spain. The
signiﬁcant rise in price of Metoject® compared with other pre-
sentations of metotrexate justiﬁes performing an economic evalu-
ation comparing it with the administration of oral leﬂunomide
(Arava®). Arava® has lower drug and monitoring related costs
than Metoject®, while not statistically signiﬁcant differences in
other direct and indirect costs have been observed between the
treatments.
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OBJECTIVES: Rituximab is an anti-CD20 monoclonal antibody
with demonstrated efﬁcacy for patients with rheumatoid arthritis
who had inadequate response to anti-TNF therapies (Cohen
et al. 2005). The primary objective of this analysis was to esti-
mate the total cost of rituximab therapy and to compare it with
inﬂiximab, adalimumab and etanercept under a private payer
perspective in Brazil. A budget impact analysis (BIA) of the
incorporation of rituximab was also performed. METHODS: We
assumed the same efﬁcacy for the comparators as there is not any
head-to-head clinical trial available until date and indirect com-
parisons showed higher ACR response rates for Mabthera.
Direct annual medical costs for biological drugs, IV administra-
tion, weekly metotrexate (MTX) and routine exams were taken
from a Delphi panel with Brazilian rheumatologists. Base case
dosages considered were: rituximab (2 g at every 8 months),
inﬂiximab (4 mg/kg at weeks 0, 2, 6 and then at every 8 weeks);
adalimumab (40 mg every other week) and etanercept (50 mg
per week). Local administration costs were obtained from Schei-
nberg et al. (2005). Costs were reported in 2007 Brazilian Reais
and discounted at a 5% rate in the BIA. Therapies were evaluated
using a 5-year horizon. In order to assess uncertainty, one and
two-way sensitivity analyses were also performed. RESULTS: In
the base case scenario, rituximab therapy resulted in a total
annual cost of R$ 45,647 per patient. Total annual costs per
patient for inﬂiximab, adalimumab and etanercept were R$
78,638; R$ 89,943 and R$ 119,170 respectively. In the BIA,
rituximab therapy resulted in total savings of R$ 91,006,061 in
5 years. Results were sensitive to dosage schedule (rituximab and
inﬂiximab) and drug acquisition costs. CONCLUSION: Results
suggest that therapy with rituximab is a cost-saving alternative
for patients with rheumatoid arthritis in the Brazilian private
health care system, unfettering resources for other disease areas.
PAR15
IMPACT OF CO-MORBIDITY BURDEN ON REAL WORLD
HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTS
INITIATING ANTI-TUMOR NECROSIS FACTORTHERAPY
Tang B1, Rahman MI1, Stephenson JJ2, Quimbo R2, Naim A1,
Thompson HC1, Dabbous O1
1Centocor, Inc, Horsham, PA, USA, 2HealthCore, Inc,Wilmington, DE,
USA
OBJECTIVES: Evaluate the impact of co-morbidity on the real
world health care costs of rheumatoid arthritis (RA) patients
who received anti-tumor necrosis factor (anti-TNF) therapy.
METHODS: A retrospective study was conducted using the
HealthCore Integrated Research Database from Blue Cross Blue
Shield plans. The study population consisted of RA patients
initiating anti-TNF therapy (adalimumab, etanercept or inﬂix-
imab) between January 1, 2003 and June 30, 2005 (index date).
All patients had >=6 months continuous plan enrollment before
and >=12 months after the index date of initiating anti-TNF
therapy. All-cause health care costs (inpatient, emergency depart-
ment visits, ofﬁce visits, outpatient services, non-TNF prescrip-
tion drugs) were calculated for the 6-month baseline pre- and
12-month post-index periods. A generalized linear model was
developed to assess the association between comorbidity burden,
as assessed by the Charlson Co-morbidity Index (CCI), and total
all-cause health care costs post-index period while controlling
for other potential confounding variables. Comparisons were
made between two mutually exclusive cohorts based on the
co-morbidity level, DCI > 0 vs. DCI = 0 (no co-morbidity).
RESULTS: In total, 2405 RA patients were analyzed; 71% were
female and the mean age was 48 years. During the 6 month
pre-index period, 16% of patients were identiﬁed with osteoar-
thritis, 12% with hypertension, 8% with diabetes, and 4.5%
with cardiovascular events. After adjusting for baseline all-cause
health care costs, age, gender, anti-TNF use, and several comor-
bidities of interest (osteoarthritis, hypertension, diabetes, and
cardiovascular events), patients in the DCI > 0 cohort (n = 1832)
had 12% higher total all-cause health care costs ($6795 vs.
$6072) compared with patients in the DCI = 0 cohort (n = 573)
after initiation of anti-TNF therapy (P < 0.0001). CONCLU-
SION: High co-morbidity burden among RA patients on anti-
TNF therapy is associated with an increase in total all-cause
health care costs. Additional analyses are recommended to deter-
mine the clinical, economic and humanistic outcomes associated
with the use of anti-TNF therapies.
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